Scots say yes to BMS/Pfizer's Eliquis and BI's Trajenta
This article was originally published in Scrip
Executive Summary
Scotland's health technology appraisal body, the Scottish Medicines Consortium, has given the green light to Bristol-Myers Squibb/Pfizer's Eliquis (apixaban) for stroke prevention and Boehringer Ingelheim's Trajenta (linagliptin) for improving glyecamic control in type 2 diabetes patients.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.